Further RNA SEQ analysis revealed that the expression of chemokine CCL2 (its coding gene is CCL2) was significantly downregulated in deguelin treated GBM cells, and CCL2 is known to be closely associated with NF-κB signaling pathway. The gene discussed is CCL2; the disease is glioblastoma.